COVID-19

Maternal COVID-19 infection raises concerns about neurodevelopmental disorders in children, emphasizing the need for effective fever and infection management during pregnancy.

In children and adolescents, reinfection with COVID-19 increased the risk of worsened long COVID outcomes.

COVID-19 mRNA vaccines enhance immune checkpoint inhibitor effectiveness in cancer therapy, significantly improving survival rates for patients with advanced tumors.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

In a Swedish cohort, young women with symptomatic long COVID were found to be at higher risk of postural orthostatic tachycardia syndrome (POTS), conferring additional burden.

Many factors lead to policy change and market viability, but none more than perceived need and desire to receive a service.

As one of the most prescribed medications worldwide, proton pump inhibitor use could serve as a bulwark against severe outcomes in hospitalized adults with COVID-19.

Pulmonary fibrosis was observed in many patients with severe COVID-19 in a retrospective cohort study, indicating the need for more effective care and prevention.

New research raises questions regarding the efficacy of nirmatrelvir-ritonavir in preventing long COVID, with limited protection found among older adults and high-risk individuals.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend that COVID-19 vaccines be administered through individual-based decision-making.

Enrollment in the Supplemental Nutrition Assistance Program or another food assistance program could help ameliorate food insecurity that contributes to long COVID.

Pharmacists face challenges as recent federal policy changes threaten their expanded roles in vaccination and public health, impacting patient access to care.

According to phase 3 trial results, Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine demonstrated significant immune responses in older adults and individuals at high risk for severe COVID-19.

E. Camille Vaughan, MD, MS, highlights how pharmacists can build patient trust, encourage vaccination, and use simple strategies to spark conversations with hesitant individuals.

E. Camille Vaughan, MD, MS, addresses how state-level differences and potential new prescription requirements could impact patient access to COVID-19 vaccines this fall.

E. Camille Vaughan, MD, MS, highlights the key role pharmacists play in providing clear, trusted guidance for patients seeking COVID-19 vaccines this fall.

Azelastine, commonly used in nasal sprays to combat allergies, was found to reduce the incidence of SARS-CoV-2 among healthy controls in a phase 2 trial.

Allison Hill, PharmD, RPh, emphasized that pharmacists must stay updated on ACIP and state-level guidance following HHS’s changes to COVID-19 vaccine authorizations.

COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.

The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.

Rhinovirus infection, which causes the common cold, could offer infected children more respiratory pathway protection from SARS-CoV-2 infection.

Alyssa Modic, PharmD, emphasizes the importance of evidence-based advocacy and continuous education as vaccine recommendations evolve.

The development of multisystem inflammatory syndrome in children infected with SARS-CoV-2 was associated with more marked shifts in metabolic parameters, leading to increased cardiovascular disease risk.

Individuals who have survived childhood cancer had a higher risk of developing a severe COVID-19 infection, while exhibiting a lower risk of contracting the virus.

Designed for use in Celiac disease, larazotide was found to hasten resolution of multisystem inflammatory syndrome symptoms in children with the condition.